Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function

Area of Science:

• Dermatology
• Pharmacology
• Immunology

Background:

• Olopatadine hydrochloride is an antiallergic agent with histamine H(1) receptor antagonistic properties.
• Chronic inflammatory dermatitis and impaired skin barrier function are significant health concerns.

Purpose of the Study:

• To investigate the efficacy of olopatadine in treating chronic inflammatory dermatitis and impaired skin barrier functions.
• To assess olopatadine's effects on inflammation, cytokine production, and skin barrier parameters in a rat model.

Main Methods:

• Oxazolone-induced dermatitis model in rats.
• Oral administration of olopatadine (1 and 3 mg/kg/day).
• Measurements included ear thickness, cytokine levels (IFN-gamma, IL-4), scratching episodes, transepidermal water loss (TEWL), and hyaluronic acid (HA) levels.

Main Results:

• Olopatadine significantly reduced ear swelling and scratching episodes.
• The drug inhibited the increase of interferon-gamma (IFN-gamma) and nerve growth factor.
• Olopatadine improved skin barrier function by reducing TEWL and increasing HA levels, also stimulating HA production in fibroblasts.

Conclusions:

• Olopatadine suppresses inflammation and scratching in dermatitis by inhibiting cytokine production.
• Olopatadine actively repairs skin barrier function, suggesting a dual mechanism of action.
• These findings highlight olopatadine's potential as a therapeutic agent for inflammatory skin diseases.